|
1
|
Court A, Laville D, Dagher S, Grosjean V, Dal-Col P, Yvorel V, Casteillo F, Bayle-Bleuez S, Vergnon JM, Forest F. Anti-CK7/CK20 Immunohistochemistry Did Not Associate with the Metastatic Site in TTF-1-Negative Lung Cancer. Diagnostics (Basel) 2022; 12:diagnostics12071589. [PMID: 35885495 PMCID: PMC9317980 DOI: 10.3390/diagnostics12071589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 06/27/2022] [Accepted: 06/28/2022] [Indexed: 11/27/2022] Open
Abstract
Anti-CK7 and anti-CK20 immunohistochemistry is sometimes used to establish a diagnosis of primary lung cancer. We performed a retrospective study on the value of anti-CK7 and anti-CK20 immunohistochemistry in 359 biopsies of patients with suspected lung carcinoma in order to assess the usefulness of these antibodies in the evaluation of lung tumors in biopsies. Our results showed TTF-1 positivity in 73.3% of patients. EGFR mutations and ALK rearrangements were significantly different between TTF-1 positive and TTF-1 negative tumors (p < 0.001 and p = 0.023, respectively). Our results show a significant difference (p < 0.001) between TTF-1 positive and TTF-1 negative carcinomas with a median survival of 21.97 months (CI95% = 17.48−30.9 months) and 6.52 months (CI95% = 3.34−10.3 months), respectively. In the group of TTF-1 negative patients, anti-CK7 and CK20 immunohistochemistry was performed in 70 patients and showed CK7+/CK20- staining in 61 patients (87.1%), CK7-/CK20- in 4 patients (5.7%), CK7+/CK20+ in 3 patients (4.3%), and CK7-/CK20- in 2 patients (2.8%). No specific or molecular pattern was found in these groups of CK7/CK20 combinations. In total, this work brings arguments concerning the uselessness of anti-CK7/CK20 immunohistochemistry in the case of suspicion of primary lung cancer in biopsies.
Collapse
Affiliation(s)
- Alice Court
- Department of Pathology, University Hospital of Saint Etienne, 42055 Saint Etienne, France; (A.C.); (D.L.); (S.D.); (V.G.); (P.D.-C.); (V.Y.); (F.C.)
| | - David Laville
- Department of Pathology, University Hospital of Saint Etienne, 42055 Saint Etienne, France; (A.C.); (D.L.); (S.D.); (V.G.); (P.D.-C.); (V.Y.); (F.C.)
| | - Sami Dagher
- Department of Pathology, University Hospital of Saint Etienne, 42055 Saint Etienne, France; (A.C.); (D.L.); (S.D.); (V.G.); (P.D.-C.); (V.Y.); (F.C.)
| | - Vincent Grosjean
- Department of Pathology, University Hospital of Saint Etienne, 42055 Saint Etienne, France; (A.C.); (D.L.); (S.D.); (V.G.); (P.D.-C.); (V.Y.); (F.C.)
| | - Pierre Dal-Col
- Department of Pathology, University Hospital of Saint Etienne, 42055 Saint Etienne, France; (A.C.); (D.L.); (S.D.); (V.G.); (P.D.-C.); (V.Y.); (F.C.)
| | - Violaine Yvorel
- Department of Pathology, University Hospital of Saint Etienne, 42055 Saint Etienne, France; (A.C.); (D.L.); (S.D.); (V.G.); (P.D.-C.); (V.Y.); (F.C.)
- Department of Molecular Biology of Solid Tumors, University Hospital of Saint Etienne, 42270 Saint Etienne, France
| | - François Casteillo
- Department of Pathology, University Hospital of Saint Etienne, 42055 Saint Etienne, France; (A.C.); (D.L.); (S.D.); (V.G.); (P.D.-C.); (V.Y.); (F.C.)
| | - Sophie Bayle-Bleuez
- Department of Pneumology, University Hospital of Saint Etienne, 42270 Saint Etienne, France; (S.B.-B.); (J.-M.V.)
| | - Jean-Michel Vergnon
- Department of Pneumology, University Hospital of Saint Etienne, 42270 Saint Etienne, France; (S.B.-B.); (J.-M.V.)
| | - Fabien Forest
- Department of Pathology, University Hospital of Saint Etienne, 42055 Saint Etienne, France; (A.C.); (D.L.); (S.D.); (V.G.); (P.D.-C.); (V.Y.); (F.C.)
- Department of Molecular Biology of Solid Tumors, University Hospital of Saint Etienne, 42270 Saint Etienne, France
- Correspondence: ; Tel.: +33-(0)-4-77-12-77-34; Fax: +33-(0)-4-77-82-82-96
| |
Collapse
|
|
2
|
Forest F, Laville D, Habougit C, Da Cruz V, Casteillo F, Yvorel V, Bard-Sorel S, Godard W, Picot T, Tiffet O, Perrot JL, Péoc'h M. Histopathologic and molecular profiling of lung adenocarcinoma skin metastases reveals specific features. Histopathology 2021; 79:1051-1060. [PMID: 34313338 DOI: 10.1111/his.14463] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 07/20/2021] [Accepted: 07/25/2021] [Indexed: 12/09/2022]
Abstract
AIMS Little is known regarding the histopathological and molecular features of lung adenocarcinoma skin metastases. Our study is the largest to comprehensively explore these to date. METHODS AND RESULTS We performed a retrospective cohort study analysing 42 lung adenocarcinoma skin metastasis samples obtained from a database of 2659 lung adenocarcinomas collected between 2010 to 2020. EGFR exon 19 deletion was detected in one patient, and KRAS mutations were detected in 12 (33.3%) patients. The PD-L1 tumour proportion score was <1% in 27 patients, ≥1% and <50% in 8 patients, ≥50% in 6 patients, and not assessable in one patient. We showed that the predominant histopathologic subtype is different from that at other metastatic sites (p=0.024). TTF-1 was more often negative in skin metastases compared to other sites (p<0.001). The EGFR mutation rate tended to be lower for skin metastases compared to other sites (p=0.079). Skin metastases were associated with a high rate of PD-L1-negative cases (p=0.022). CONCLUSION Our work shows that the skin metastases of lung adenocarcinoma have a specific histopathologic profile.
Collapse
Affiliation(s)
- Fabien Forest
- University Hospital of Saint Etienne. North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France.,University Hospital of Saint Etienne. North Hospital, Plateforme de biologie moléculaire des tumeurs solides, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France.,Corneal Graft Biology, Engineering, and Imaging Laboratory, BiiGC, EA2521, Federative Institute of Research in Sciences and Health Engineering, Faculty of Medicine, Jean Monnet University, Saint-Etienne, France
| | - David Laville
- University Hospital of Saint Etienne. North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - Cyril Habougit
- University Hospital of Saint Etienne. North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - Vanessa Da Cruz
- University Hospital of Saint Etienne. North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - François Casteillo
- University Hospital of Saint Etienne. North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - Violaine Yvorel
- University Hospital of Saint Etienne. North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France.,University Hospital of Saint Etienne. North Hospital, Plateforme de biologie moléculaire des tumeurs solides, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | | | - William Godard
- University Hospital of Saint Etienne. North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France.,Institut de Pathologie du Forez, 11 Rue de la République, 42000, Saint-Étienne, France
| | - Tiphanie Picot
- University Hospital of Saint Etienne. North Hospital, Plateforme de biologie moléculaire des tumeurs solides, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - Olivier Tiffet
- University Hospital of Saint Etienne. North Hospital, Department of Thoracic Surgery, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - Jean-Luc Perrot
- University Hospital of Saint Etienne. North Hospital, Department of Dermatology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - Michel Péoc'h
- University Hospital of Saint Etienne. North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| |
Collapse
|